Focused On-demand Library for Nck-associated protein 1-like

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P55160

UPID:

NCKPL_HUMAN

Alternative names:

Hematopoietic protein 1; Membrane-associated protein HEM-1

Alternative UPACC:

P55160; B4DUT5; Q52LW0

Background:

Nck-associated protein 1-like, also known as Hematopoietic protein 1 and Membrane-associated protein HEM-1, plays a pivotal role in the regulation of the actin cytoskeleton. It is crucial for lymphocyte development, activation, proliferation, and homeostasis, as well as for erythrocyte membrane stability. This protein is a component of the WAVE2 complex, facilitating F-actin polymerization and influencing T-cell and neutrophil migration.

Therapeutic significance:

The protein's involvement in Immunodeficiency 72 with autoinflammation and lymphoproliferation highlights its potential as a target for therapeutic intervention. Understanding the role of Nck-associated protein 1-like could open doors to potential therapeutic strategies for treating this complex immunologic disorder.